Independent Investment Research - Chimeric Therapeutics Limited (ASX: CHM) Chimeric Therapeutics Limited (ASX: CHM)

Report

Independent Research

Chimeric Therapeutics Limited (ASX: CHM)

Full report available at

Chimeric Therapeutics Limited (ASX: CHM) is a clinical stage cell therapy company that is seeking to develop novel cell therapies to potentially treat a range of cancers. The Company was listed in January 2021 and has a portfolio of autologous CAR-T candidates which it is seeking to develop and has recently expanded the portfolio with the option to licence an allogeneic CAR-NK platform.

19/12/2021 24 EN

Underlying

Chimeric Therapeutics Limited

See profile

Provider

Independent Investment Research

Independent Investment Research, "IIR", is an independent investment research house based in Australia and the United States. IIR specialises in the analysis of high quality commissioned research for Brokers, Family Offices and Fund Managers. IIR distributes its research in Asia, United States and the Americas. IIR does not participate in any corporate or capital raising activity and therefore it does not have any inherent bias that may result from research that is linked to any corporate/ capital raising activity.

IIR was established in 2004 under Aegis Equities Research Group of companies to provide investment research to a select group of retail and wholesale clients. Since March 2010, IIR (the Aegis Equities business was sold to Morningstar) has operated independently from Aegis by former Aegis senior executives/shareholders to provide clients with unparalleled research that covers listed and unlisted managed investments, listed companies, structured products, and IPO's.

IIR takes great pride in the quality and independence of our analysis, underpinned by high caliber staff and a transparent, proven and rigorous research methodology.

See profile

Analysts

Independent Research

Other Reports on these Companies

Bluejay Mining plc

Full Report Available at Bluejay Mining plc Bluejay Mining plc (“Bluejay”) is an exploration and development company with projects in Greenland and Finland. The company is working towards construction of the fully permitted Dundas Ilmenite Project (“Dundas”) and advancing its other existing projects in Greenland and Finland. The company has secured world-class partners for its Disko-Nuussuaq (“Disko”) and Enonkoski projects that will enable the company to participate in the development of these attractive assets without immediate funding obligations. With the commissioning of Dundas, Blue...

January 5, 2022 January 5, 2022 30 EN

Independent Research

Independent Research

LMI Monthly Update - Are You Doubling Down on Your Aussie Large Cap Exposure?

Full Report Available at Are You Doubling Down on Your Aussie Large Cap Exposure? The release of financial accounts is one of the few occasions we get a look at the full portfolio of a LIC or LIT. With the completion of results season for the majority of LICs and LITs at August-end we got a look at the portfolios and thought it was a good time to take a look at whether Australian Large Cap LICs offer a level of diversification or whether investors are doubling down on their stock exposure in the event multiple Australian Large Cap LICs are owned. Below we take a look at the overlap of stocks...

December 19, 2021 December 19, 2021 10 EN

Independent Research

Independent Research

Loomis Sayles Global Equity Fund (Quoted Managed Fund) (ASX code: LGSE)

Full Report Available at Loomis Sayles Global Equity Fund (Quoted Managed Fund), (ASX: LSGE) (the “Fund”) is a newly listed Exchange Traded Managed Fund (ETMF), also known as an Active ETF. The Fund was listed on 1 October 2021 and provides exposure to the Loomis Sayles Global Equity Opportunities Strategy (the “Strategy”), which was established in October 2004. The Responsible Entity (RE) is Investors Mutual Limited who has appointed Loomis, Sayles & Company, L.P as the Investment Manager (“Loomis Sayles” or the “Manager”) of the Fund. Loomis Sayles is a global asset manager that was establ...

December 19, 2021 December 19, 2021 18 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Chimeric Therapeutics Limited (ASX: CHM)

Bluejay Mining plc

LMI Monthly Update - Are You Doubling Down on Your Aussie Large Cap Exposure?

Loomis Sayles Global Equity Fund (Quoted Managed Fund) (ASX code: LGSE)

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe